Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-15

Clinical Trial Update: Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Open-label extension trial for PTI-125 (simufilam) in mild-to-moderate Alzheimer's disease has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PTI-125 (simufilam)

Snippet

Sponsor: Cassava Sciences, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-08-15